Mid-stage evidence-based digital health technologies, which have achieved proof-of-principle, are encouraged to apply for the ANDHealth+ 2017 Program, which opened last week to support projects to progress technology towards investment.
Selected teams will have $60,000 of support for project expenses, plus significant in-kind access to specialist third party services, and advisory support from people with proven track record in digital health commercialisation.
Applicants are invited to apply to access support from proven experts to undertake a significant piece of work focused on securing the clinical and/or commercial evidence to enable the raising of growth capital and progress a market entry strategy. No transfer of equity or intellectual property rights is required to be a participant in the ANDHealth+ program.
Each project selected will be supported by up to $60,000 to access specialist third party services and activities, plus up to $100,000 of in kind support from ANDHealth members and facilitated introductions to national and international networks of investors, global healthcare and technology companies and specialised service providers.
Applications for the ANDHealth+ 2017 Program close 4 August 2017.
ANDHealth has received funding through the MTPConnect Project Fund Program – a matched program investing in big, bold ideas to improve the productivity, competitiveness and innovative capacity of Australia’s medical technology, biotechnology and pharmaceutical sector. MTPConnect is supported by the Australian Government Industry Growth Centres Initiative.
The ANDHealth initiative is supported by AusBiotech, the Murdoch Children’s Research Institute, RMIT University, Novartis Pharmaceuticals, Planet Innovation, Curve Tomorrow, GP2U Telehealth, HealthXL and HPM Executive.
More information and how to apply is available online.